Drug Reference for FDA Approved Migraine Drugs @ Neurotransmitter.net


Advertisement



Generic Name:
acetaminophen, aspirin, and caffeine

Trade Name:
Excedrin Migraine ® [Bristol-Myers Squibb]


Dosage Forms/Routes:
tablet/oral

Major Metabolites:
Acetaminophen:
acetaminophen glucuronide; acetaminophen sulfate
Aspirin:
salicylic acid;
gentisic acid;
salicyluric acid
Caffeine:
paraxanthine;
theophylline;
theobromine

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

Initial Approval:
01/14/1998


Manufacturers:

[FDA Search]

Product Label :
[
Link]

Indications:
Excedrin Migraine is indicated for the treatment of migraine.

Possible Mechanisms of Action:
Acetaminophen inhibits cyclooxygenase-2 (COX-2) when concentrations of arachidonic acid and peroxides are low (1). In addition, acetaminophen inhibits the apozyme of tryptophan-2,3-dioxygenase in the liver (2).

Aspirin (acetylsalicylic acid) acetylates vascular COX-2, which causes it to catalyze the synthesis of aspirin-triggered 15-epi-lipoxin intermediates rather than the synthesis of prostaglandin intermediates (3). Aspirin is also an irreversible inhibitor of cyclooxygenase-1 (COX-1) (4).

Caffeine is a competitive antagonist at A1 and A2A adenosine receptors (5). The drug is also a nonselective phosphodiesterase inhibitor; however, normal consumption of caffeine is not likely to induce this effect (6).

Chemical Classes:
acetanilide derivative (acetaminophen), salicylic acid derivative (aspirin), and methylxanthine (caffeine)
"3D" Structure (Requires Chime):
[Link (acetaminophen)]
[Link (aspirin)]

[Link (caffeine)]

Generic Name:
almotriptan malate

Trade Name:
Axert ® [Ortho-McNeil]

IUPAC Name:
N,N-dimethyl-2-[5-(pyrrolidin-
1-ylsulfonylmethyl)-1H-indol-
3-yl]-ethanamine; 2-
hydroxybutanedioic acid

Dosage Forms/Routes:
Tablet/oral

Major Metabolites:
M2 (formed by pyrrolidine ring oxidation);
M6 (indole acetic acid derivative);
M8 (glucuronide acid metabolite of M6) (see McEwen et al., 2004)

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
05/07/2001 


Manufacturers:

[FDA Search]

Prescribing Information:
[
Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C21H31N3O7S

Molecular Mass:
469.553 g/mol

Indications:
Almotriptan tablets are indicated for the acute treatment of migraine with or without aura in adults.

Almotriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS in the prescribing information). Safety and effectiveness of almotriptan have not been established for cluster headache, which is present in an older, predominantly male population.

Possible Mechanisms of Action:
Almotriptan is an agonist at serotonin 5-HT1B, 5-HT1D, and 5-HT1F receptors (7).

Chemical Class:
triptan

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link] 

Generic Name:
aspirin

Trade Name:
Aspirin Migraine ® [Bayer]

IUPAC Name:
2-acetyloxybenzoic acid


Dosage Forms/Routes:
tablet/oral

Major Metabolites:
salicylic acid;
gentisic acid;
salicyluric acid

Database Search Links:
[PubMed]
[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
10/18/2001


Manufacturers:

[FDA Search]

Product Label :
[
Link]

Epocrates:
[Link]

Empirical Formula:
C9H8O4

Molecular Mass:
180.157 g/mol

Indications:
Excedrin Migraine is indicated for the treatment of migraine.

Possible Mechanisms of Action:
Aspirin (acetylsalicylic acid) acetylates vascular COX-2, which causes it to catalyze the synthesis of aspirin-triggered 15-epi-lipoxin intermediates rather than the synthesis of prostaglandin intermediates (3). Aspirin is also an irreversible inhibitor of cyclooxygenase-1 (COX-1) (4).

Chemical Classes:
salicylic acid derivative

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link]

Generic Name:
caffeine and ergotamine tartrate

Trade Name:
Cafergot ® [Novartis]

IUPAC Name (caffeine) :
1,3,7-trimethylpurine-2,6-dione

Common Chemical Name (ergotamine tartrate):
Ergotaman-3',6', 18-trione,
12'- hydroxy-2'-methyl-5'-
(phenyl-methyl)-,(5'(alpha))-,
[R-(R*,R*)]-2, 3-dihydroxybutanedioate(2:1)
(tartrate)


Dosage Forms/Routes:
Tablet/oral;
Suppository/rectal

Major Metabolites:
Caffeine:
paraxanthine;
theophylline;
theobromine
Ergotamine:
M1; M2; M1-Iso; M2-Iso (see Moubarak and Rosenkrans Jr., 2000)

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]

Initial Approval:
11/26/1948


Manufacturers:

[FDA Search]

Prescribing Information:
[
Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C45H51N9O12

Molecular Mass:
909.94 g/mol

Indications:
The combination of caffeine and ergotamine is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so-called "histaminic cephalalgia."

Possible Mechanisms of Action:
Caffeine is a competitive antagonist at A1 and A2A adenosine receptors (5). The drug is also a nonselective phosphodiesterase inhibitor; however, normal consumption of caffeine is not likely to induce this effect (6).

Ergotamine is an agonist at serotonin 5-HT1A (8), 5-HT1B (8), 5-HT1D (8), 5-HT2A (9), 5-HT2B (9), 5-HT2C (9), 5-HT5A (10), and 5-HT6 (11) receptors. Ergotamine also binds relatively weakly to serotonin 5-HT1F receptors (12), alpha-2A-adrenoceptors (13), and alpha-2B-adrenoceptors (13). In addition, ergotamine may accelerate the transport of glutamate mediated by hGluT-1 (19).

Chemical Class:
methylxanthine (caffeine) and ergot alkaloid (ergotamine)

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link (caffeine)]
[Link (ergotamine)]

Generic Name:
dihydroergotamine mesylate

Trade Name:
D.H.E. 45 ® [Valeant]

Common Chemical Name:
ergotaman-3',6',18-
trione,9,10-dihydro-12'-
hydroxy-2'-methyl-5'-
(phenylmethyl) (5'a)-, monomethanesulfonate

Dosage Forms/Routes:
Injectable/injection;
Spray, metered/nasal

Major Metabolite:
8'-hydroxy-dihydroergotamine

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
04/12/1946


Manufacturers:

[FDA Search]

Prescribing Information:
[
Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C34H41N5O8S

Molecular Mass:
679.784 g/mol

Indications:
Dihydroergotamine is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.

Possible Mechanisms of Action:
Dihydroergotamine is an agonist at serotonin 5-HT1A (14), 5-HT1B (14), 5-HT1D (14), 5-HT1F (15), 5-HT2B (16), and 5-HT2C (16) receptors. The drug is an antagonist at serotonin 5-HT2A receptors (17). Dihydroergotamine may also bind to alpha-1-adrenoceptors, alpha-2-adrenoceptors, and dopamine D2 receptors (18). In addition, dihydroergotamine may accelerate the transport of glutamate mediated by hGluT-1 (19).

Chemical Class:
semisynthetic, hydrogenated ergot alkaloid

PubChem 2D Structure:

Generic Name:
divalproex sodium

Trade Name:
Depakote ® [
Abbott Labs]

IUPAC Name:
sodium; 2-propylpentanoate;
2-propylpentanoic acid

Major Metabolites:
3-keto-valproic acid;
trans-2-ene valproic acid;
valproic acid glucuronide

Dosage Forms/Routes:
Tablet (delayed release)/oral;
Capsule (delayed release pellets)/oral;
Tablet (extended release)/oral

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
03/10/1983


Manufacturers:

[FDA Search]

Prescribing Information:
[Link 1]
[Link 2] (ER)

RxList:
[Link]

Epocrates:
[Link]

Empirical Formula:
C16H31NaO4

Molecular Mass:
310.405 g/mol

Indications:
Prophylaxis of migraine headaches; monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures; sole or adjunctive therapy in the treatment of simple and complex absence seizures; adjunct for the treatment of patients with multiple seizure types that include absence seizures; manic episodes associated with bipolar disorder

Possible Mechanisms of Action:
Divalproex is a histone deacetylase inhibitor (20). The enhancement of gamma-aminobutyric acid (GABA) activity by divalproex is possibly due to the downregulation of GAT-1 and GAT-3 GABA transporter proteins by the drug (21); the cause of this effect is currently unknown. Divalproex also inhibits succinate semialdehyde dehydrogenase (22).
At voltage-gated sodium channnels, divalproex shifts the voltage dependence of steady-state inactivation to more hyperpolarized potentials (23); the degree to which this action occurs at therapeutically relevant concentrations in humans is currently not known (24). Finally, divalproex may inhibit T-type calcium channels (25).

Chemical Class:
carboxylic acid derivative

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link] 

Generic Name:
eletriptan hydrobromide

Trade Name:
Relpax ® [Pfizer]

IUPAC Name:
3-[(1-methylpyrrolidin-2-yl)
methyl]-5-(2-
phenylsulfonylethyl)-1H-indole
hydrobromide

Dosage Forms/Routes:
Tablet/oral

Major Metabolite:
N-desmethyl eletriptan

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
12/26/2002


Manufacturers:

[FDA Search]

Prescribing Information:
[
Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C22H27BrN2O2S

Molecular Mass:
463.432 g/mol

Indications:
Eletriptan tablets are indicated for the acute treatment of migraine with or without aura in adults.

Eletriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS in the prescribing information). Safety and effectiveness of eletriptan have not been established for cluster headache, which is present in an older, predominantly male population.

Possible Mechanisms of Action:
Eletriptan is an agonist at serotonin 5-HT1B, 5-HT1D, and 5-HT1F receptors (26).

Chemical Class:
triptan

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link] 

Generic Name:
ergotamine tartrate

Trade Name:
Ergomar ® [Harvest]

Common Chemical Name:
Ergotaman-3',6', 18-trione,
12'-hydroxy-2'-methyl-5'-
(phenyl-methyl)-,(5'(alpha))-
,[R-(R*,R*)]-2, 3-
dihydroxybutanedioate(2:1)
(tartrate)

Dosage Forms/Routes:
Tablet/sublingual

Major Metabolites:
M1; M2; M1-Iso; M2-Iso (see Moubarak and Rosenkrans Jr., 2000)

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
02/24/1983


Manufacturers:

[FDA Search]

Prescribing Information:
[
Link]

RxList:
[
Link]

Empirical Formula:
C37H41N5O11

Molecular Mass:
731.749 g/mol

Indications:
Ergotamine is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so-called "histaminic cephalalgia."

Possible Mechanisms of Action:
Ergotamine is an agonist at serotonin 5-HT1A (8), 5-HT1B (8), 5-HT1D (8), 5-HT2A (9), 5-HT2B (9), 5-HT2C (9), 5-HT5A (10), and 5-HT6 (11) receptors. Ergotamine also binds relatively weakly to serotonin 5-HT1F receptors (12),
alpha-2A-adrenoceptors (13), and alpha-2B-adrenoceptors (13). In addition, ergotamine may accelerate the transport of glutamate mediated by hGluT-1 (19).

Chemical Class:
ergot alkaloid

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link]

Generic Name:
frovatriptan succinate

Trade Name:
Frova ® [Endo]

IUPAC Name:
butanedioic acid; 6-
methylamino-6,7,8,9-
tetrahydro-5H-carbazole-3-
carboxamide; hydrate

Dosage Forms/Routes:
Tablet/oral

Major Metabolites:
hydroxylated frovatriptan;
N-acetyl desmethyl frovatriptan; hydroxylated N-acetyl desmethyl frovatriptan;
desmethyl frovatriptan

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
11/08/2001 


Manufacturers:

[FDA Search]

Prescribing Information:
[
Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C18H25N3O6

Molecular Mass:
379.408 g/mol

Indications:
Frovatriptan tablets are indicated for the acute treatment of migraine with or without aura in adults.

Frovatriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS in the prescribing information). Safety and effectiveness of frovatriptan have not been established for cluster headache, which is present in an older, predominantly male population.

Possible Mechanisms of Action:
Frovatriptan is an agonist at 5-HT1B (27), 5-HT1D (27), and 5-HT1F (28) receptors. At higher concentrations, the drug is an agonist at 5-HT7 receptors (27, 29).

Chemical Class:
triptan

PubChem 2D Structure:

Generic Name:
ibuprofen

Trade Name:
Motrin Migraine Pain ® [McNeil]

IUPAC Name:
2-[4-(2-
methylpropyl)phenyl]propanoic acid


Dosage Forms/Routes:
Tablet/oral

Major Metabolites:
(+)-2-4'-(2-hydroxy-2-
methylpropyl)-phenylpropionic acid;
(+)-2-4'-(2-carboxypropyl)-
phenylpropionic acid

Database Search Links:
[PubMed]
[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
05/18/1984


Manufacturers:

[FDA Search]

Product Label :
[
Link]

Epocrates:
[Link]

Empirical Formula:
C13H18O2

Molecular Mass:
206.281 g/mol

Indications:
Motrin Migraine Pain is indicated for the treatment of migraine.

Possible Mechanisms of Action:
Ibuprofen inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) (45). It is a less potent inhibitor of the latter enzyme (45).

Chemical Class:
propionic acid derivative

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link]

Generic Name:
ibuprofen potassium

Trade Name:
Advil Migraine ® [Wyeth]

IUPAC Name:
potassium 2-[4-(2-
methylpropyl)phenyl]propanoate

Dosage Forms/Routes:
Capsule/oral

Major Metabolites:
(+)-2-4'-(2-hydroxy-2-
methylpropyl)-phenylpropionic acid;
(+)-2-4'-(2-carboxypropyl)-
phenylpropionic acid

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
04/20/1995


Manufacturers:

[FDA Search]

Product Label:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C13H17KO2

Molecular Mass:
244.371 g/mol

Indications:
Advil Migraine is indicated for the treatment of migraine.

Possible Mechanisms of Action:
Ibuprofen inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) (45). It is a less potent inhibitor of the latter enzyme (45).

Chemical Class:
propionic acid derivative

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link]

Generic Name:
naratriptan hydrochloride

Trade Name:
Amerge ® [GlaxoSmithKline]

IUPAC Name:
N-methyl-2-[3-(1-methyl-4-
piperidyl)-1H-indol-5-yl]-
ethanesulfonamide hydrochloride

Dosage Forms/Routes:
Tablet/oral

Major Metabolite:
N-oxide of naratriptan

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
02/10/1998


Manufacturers:

[FDA Search]

Prescribing Information:
[
Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C17H26ClN3O2S

Molecular Mass:
371.926 g/mol

Indications:
Naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults.

Naratriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS in the prescribing information). Safety and effectiveness of naratriptan have not been established for cluster headache, which is present in an older, predominantly male population.

Possible Mechanisms of Action:
Naratriptan is an agonist at serotonin 5-HT1A (30), 5-HT1B (30), 5-HT1D (30), and 5-HT1F (31) receptors.

Chemical Class:
triptan

PubChem 2D Structure:

Generic Name:
propranolol hydrochloride

Trade Name:
Inderal ® [Wyeth]

IUPAC Name:
1-naphthalen-1-yloxy-3-
propan-2-ylamino-propan-2-ol
hydrochloride

Dosage Forms/Routes:
Tablet/oral;
Extended release capsule/oral;
Injectable/injection;
Solution/oral;
Concentrate/oral

Major Metabolites:
4-hydroxypropranolol;
naphthoxylactic acid;
propranolol glucuronide

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
11/13/1967


Manufacturers:

[FDA Search]

Prescribing Information:
[
Link]
[Link] (LA)

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C16H22ClNO2

Molecular Mass:
295.804 g/mol

Indications:
Propranolol is indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. See the prescribing information for other indications of propranolol.

Possible Mechanisms of Action:
Propranolol is an antagonist at beta-1-adrenoceptors and beta-2-adrenoceptors (32).

Chemical Class:
naphthyloxy propanolamine derivative

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link]

Generic Name:
rizatriptan benzoate

Trade Name:
Maxalt ® [Merck]

IUPAC Name:
benzoic acid; N,N-dimethyl-2-
[5-(1,2,4-triazol-1-ylmethyl)-
1H-indol-3-yl]-ethanamine

Dosage Forms/Routes:
Tablet/oral;
Tablet/orally disintegrating

Major Metabolite:
triazolomethyl-indole-3-acetic acid

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
06/29/1998


Manufacturers:

[FDA Search]

Prescribing Information:
[
Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C22H25N5O2

Molecular Mass:
391.466 g/mol

Indications:
Rizatriptan tablets are indicated for the acute treatment of migraine with or without aura in adults.

Rizatriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS in the prescribing information). Safety and effectiveness of rizatriptan have not been established for cluster headache, which is present in an older, predominantly male population.

Possible Mechanisms of Action:
Rizatriptan is an agonist at serotonin 5-HT1B (33) and 5-HT1D (33) receptors. The drug also has weak affinity for serotonin 5-HT1A, 5-HT1E, 5-HT1F, and 5-HT7 receptors (see the prescribing information).

Chemical Class:
triptan

PubChem 2D Structure:

Generic Name:
sumatriptan succinate

Trade Name:
Imitrex ® [GlaxoSmithKline]

IUPAC Name:
butanedioic acid; 1-[3-(2-
dimethylaminoethyl)-1H-indol-
5-yl]-N-methyl-
methanesulfonamide

Dosage Forms/Routes:
Tablet/oral;
Spray/nasal;
Injectable/injection


Major Metabolite:
GR49336 (an indole acetic acid analog)

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
12/28/1992


Manufacturers:

[FDA Search]

Prescribing Information:
[
Link] (tablets)
[Link] (injection)
[Link] (nasal)

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C18H27N3O6S

Molecular Mass:
413.49 g/mol

Indications:
Sumatriptan tablets are indicated for the acute treatment of migraine with or without aura in adults.

Sumatriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS in the prescribing information). Safety and effectiveness of sumatriptan have not been established for cluster headache, which is present in an older, predominantly male population.

Possible Mechanisms of Action:
Sumatriptan is an agonist at serotonin 5-HT1B (34), 5-HT1D (34), and 5-HT1F (31) receptors.

Chemical Class:
triptan

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link]

Generic Name:
topiramate

Trade Name:
Topamax ® [Ortho-McNeil]

Common Chemical Name:
2,3:4,5-Di-O-isopropylidene-
β-D-fructopyranose sulfamate

Major Metabolites:
2,3-O-des-isopropylidene-
topiramate;
10-hydroxy-topiramate

Dosage Forms/Routes:
Tablet/oral;
Capsule/oral

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
12/24/1996


Manufacturers:

[FDA Search]

Prescribing Information:
[Link]

RxList:
[Link]

Epocrates:
[Link]

Empirical Formula:
C12H21NO8S

Molecular Mass:
339.363 g/mol

Indications:
Topiramate is indicated as a prophylaxis of migraine for adults; initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures; adjunctive therapy for adults and pediatric patients ages 2-16 years with partial onset seizures or primary generalized tonic-clonic seizures; and adjunctive therapy for patients 2 years of age and older with seizures associated with Lennox-Gastaut syndrome.

Possible Mechanisms of Action:
Topiramate inhibits carbonic anhydrase isozymes such as CA II (35), CA IV (35, 36), and CA V (37). Topiramate has also been shown to inhibit both the fast and persistent components of sodium currents in neocortical cells (38). In addition, the drug may inhibit L-type calcium channels (39, 40). Topiramate also inhibits inward currents at some subtypes of kainate and AMPA glutamate receptors (41, 42). Finally, the drug may act as a histone deacetylase inhibitor (43).

Chemical Class:
sulfamated monosaccharide

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link]

Generic Name:
zolmitriptan

Trade Name:
Zomig ® [AstraZeneca]

IUPAC Name:
4-[[3-(2-dimethylaminoethyl)-
1H-indol-5-yl]methyl]
oxazolidin-2-one

Dosage Forms/Routes:
Tablet/oral
Spray/nasal
Tablet/orally disintegrating

Major Metabolite:
N-desmethyl zolmitriptan

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
11/25/1997


Manufacturers:

[FDA Search]

Prescribing Information:
[
Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C16H21N3O2

Molecular Mass:
287.357 g/mol

Indications:
Zolmitriptan tablets are indicated for the acute treatment of migraine with or without aura in adults.

Zolmitriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS in the prescribing information). Safety and effectiveness of zolmitriptan have not been established for cluster headache, which is present in an older, predominantly male population.

Possible Mechanisms of Action:
Zolmitriptan is an agonist at serotonin 5-HT1B (44), 5-HT1D (44), and 5-HT1F (31) receptors. Zolmitriptan also exhibits moderate affinity for serotonin 5-HT1A receptors (see the prescribing information)

Chemical Class:
triptan

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link]

References:

1. Graham GG, Scott KF.
Mechanism of action of paracetamol.
Am J Ther. 2005 Jan-Feb;12(1):46-55. [Abstract]

2. Daya S, Anoopkumar-Dukie S.
Acetaminophen inhibits liver trytophan-2,3-dioxygenase activity with a concomitant rise in brain serotonin levels and a reduction in urinary 5-hydroxyindole acetic acid.
Life Sci. 2000 Jun 8;67(3):235-40. [Abstract]

3. Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN.
Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial.
Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15178-83. [Full Text]

4. Ouellet M, Riendeau D, Percival MD.
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14583-8. [Full Text]

5. Fredholm, Bertil B., IJzerman, Adriaan P., Jacobson, Kenneth A., Klotz, Karl-Norbert, Linden, Joel
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Pharmacol Rev 2001 53: 527-552 [Full Text]

6. Lindaman BA, Hinkhouse MM, Conklin JL, Cullen JJ.
The effect of phosphodiesterase inhibition on gallbladder motility in vitro.
J Surg Res 2002 Jun 15;105(2):102-8 [Abstract]

7. Bou J, Domenech T, Puig J, Heredia A, Gras J, Fernandez-Forner D, Beleta J, Palacios JM.
Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine.
Eur J Pharmacol. 2000 Dec 20;410(1):33-41. [Abstract]

8. Silberstein SD.
The pharmacology of ergotamine and dihydroergotamine.
Headache. 1997;37 Suppl 1:S15-25. [Abstract]

9. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL.
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
Circulation. 2000 Dec 5;102(23):2836-41. [Full Text]

10. Sanchez-Lopez A, Centurion D, Vazquez E, Arulmani U, Saxena PR, Villalon CM.
Pharmacological profile of the 5-HT-induced inhibition of cardioaccelerator sympathetic outflow in pithed rats: correlation with 5-HT1 and putative 5-ht5A/5B receptors.
Br J Pharmacol. 2003 Oct;140(4):725-35. [Abstract]

11. Boess FG, Monsma FJ Jr, Meyer V, Zwingelstein C, Sleight AJ.
Interaction of tryptamine and ergoline compounds with threonine 196 in the ligand binding site of the 5-hydroxytryptamine6 receptor.
Mol Pharmacol. 1997 Sep;52(3):515-23. [Full Text]

12. Boess FG, Martin IL.
Molecular biology of 5-HT receptors.
Neuropharmacology. 1994 Mar-Apr;33(3-4):275-317. [Abstract]

13. Roth BL, Kroeze WK, Patel S, Lopez E.
The Multiplicity of Serotonin Receptors: Uselessly diverse molecules or an embarrasment of riches?
The Neuroscientist. 2000. 6:252-262. [PDSP Ki database]

14. Pauwels PJ, Palmier C, Dupuis DS, Colpaert FC.
Interaction of 5-HT1B/D ligands with recombinant h 5-HT1A receptors: intrinsic activity and modulation by G-protein activation state.
Naunyn Schmiedebergs Arch Pharmacol. 1998 May;357(5):490-9. [Abstract]

15. Wainscott DB, Johnson KW, Phebus LA, Schaus JM, Nelson DL.
Human 5-HT1F receptor-stimulated [35S]GTPgammaS binding: correlation with inhibition of guinea pig dural plasma protein extravasation.
Eur J Pharmacol. 1998 Jul 3;352(1):117-24. [Abstract]

16. Schaerlinger B, Hickel P, Etienne N, Guesnier L, Maroteaux L.
Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.
Br J Pharmacol. 2003 Sep;140(2):277-84. [Abstract]

17. Kalkman HO, Schneider F.
Effects of ergotamine and dihydroergotamine on 5-hydroxytryptamine-2A receptors in the isolated rat aorta.
Pharmacology. 1996 Dec;53(6):351-5. [Abstract]

18. McCarthy BG, Peroutka SJ.
Comparative neuropharmacology of dihydroergotamine and sumatriptan (GR 43175).
Headache. 1989 Jul;29(7):420-2. [Abstract]

19. Yamashita H, Kawakami H, Zhang YX, Tanaka K, Nakamura S.
Effect of amino acid ergot alkaloids on glutamate transport via human glutamate transporter hGluT-1.
J Neurol Sci. 1998 Feb 18;155(1):31-6. [Abstract]

20. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS.
Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen
J Biol Chem. 2001 Sep 28;276(39):36734-41. [Full Text]

21. Ueda Y, Willmore LJ.
Molecular regulation of glutamate and GABA transporter proteins by valproic acid in rat hippocampus during epileptogenesis.
Exp Brain Res 2000 Aug;133(3):334-9 [Abstract]

22. Johannessen CU.
Mechanisms of action of valproate: a commentatory.
Neurochem Int. 2000 Aug-Sep;37(2-3):103-10. [Abstract]

23. Vreugdenhil M, Wadman WJ.
Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis.
Epilepsia 1999 Nov;40(11):1512-22 [Abstract]

24. Loscher W.
Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.
CNS Drugs 2002;16(10):669-94 [Abstract]

25. Cutrer FM.
Antiepileptic drugs: how they work in headache.
Headache. 2001 Nov-Dec;41 Suppl 1:S3-10. [Abstract]

26. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R.
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68. [Abstract]

27. Comer MB.
Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan.
Headache. 2002 Apr;42 Suppl 2:S47-53. [Abstract]

28. Bhalla P, Sharma HS, Wurch T, Pauwels PJ, Saxena PR.
Molecular cloning and expression of the porcine trigeminal ganglion cDNA encoding a 5-ht(1F) receptor.
Eur J Pharmacol. 2002 Feb 1;436(1-2):23-33. [Abstract]

29. Jahnichen S, Glusa E, Pertz HH.
Evidence for 5-HT2B and 5-HT7 receptor-mediated relaxation in pulmonary arteries of weaned pigs.
Naunyn Schmiedebergs Arch Pharmacol. 2005 Jan;371(1):89-98. [Abstract]

30. Boers PM, Donaldson C, Zagami AS, Lambert GA.
Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT(1B/1D) receptors in the cat: implications for migraine therapy.
Cephalalgia. 2004 Feb;24(2):99-109. [Abstract]

31. Wainscott DB, Johnson KW, Phebus LA, Schaus JM, Nelson DL.
Human 5-HT1F receptor-stimulated [35S]GTPgammaS binding: correlation with inhibition of guinea pig dural plasma protein extravasation.
Eur J Pharmacol. 1998 Jul 3;352(1):117-24. [Abstract]

32. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN.
Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.
Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. [Abstract]

33. Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ.
The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs.
Br J Pharmacol. 2001 Aug;133(7):1029-34. [Abstract]

34. van den Broek RW, Bhalla P, VanDenBrink AM, de Vries R, Sharma HS, Saxena PR.
Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT(1B) and 5-HT(1D) receptor antagonists and in situ hybridization.
Cephalalgia. 2002 Mar;22(2):83-93. [Abstract]

35. Dodgson SJ, Shank RP, Maryanoff BE.
Topiramate as an inhibitor of carbonic anhydrase isoenzymes.
Epilepsia 2000;41 Suppl 1:S35-9 [Abstract]

36. Masereel B, Rolin S, Abbate F, Scozzafava A, Supuran CT.
Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties.
J Med Chem. 2002 Jan 17;45(2):312-20. [Abstract]

37. De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT.
Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies.
Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20. [Abstract]

38. Taverna, S., Sancini, G., Mantegazza, M., Franceschetti, S., Avanzini, G.
Inhibition of Transient and Persistent Na+ Current Fractions by the New Anticonvulsant Topiramate
J Pharmacol Exp Ther 1999 288: 960-968 [Full Text]

39. Zhang X, Velumian AA, Jones OT, Carlen PL.
Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate.
Epilepsia. 2000;41 Suppl 1:S52-60. [Abstract]

40. Russo E, Constanti A, Ferreri G, Citraro R, De Sarro G.
Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy.
Neuropharmacology. 2004 May;46(6):865-78. [Abstract]

41. Poulsen CF, Simeone TA, Maar TE, Smith-Swintosky V, White HS, Schousboe A.
Modulation by topiramate of AMPA and kainate mediated calcium influx in cultured cerebral cortical, hippocampal and cerebellar neurons.
Neurochem Res. 2004 Jan;29(1):275-82.Neurochem Res. 2004 Jan;29(1):275-82. [Abstract]

42. Gibbs JW 3rd, Sombati S, DeLorenzo RJ, Coulter DA.
Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons.
Epilepsia. 2000;41 Suppl 1:S10-6. [Abstract]

43. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M.
The activity of antiepileptic drugs as histone deacetylase inhibitors.
Epilepsia. 2004 Jul;45(7):737-44. [Abstract]

44. Martin GR, Robertson AD, MacLennan SJ, Prentice DJ, Barrett VJ, Buckingham J, Honey AC, Giles H, Moncada S.
Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).
Br J Pharmacol. 1997 May;121(2):157-64. [Abstract]

45. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR.
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase.
Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693-7. [Full Text]